(Z)-N-[(1S)-1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylprop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (Z)-N-[(1S)-1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylprop-2-enamide
• 化学式: C₂₁H₂₄N₂O₂
• 分子量: 336.4
• InChiKey: QMIMHUDEVKGOTQ-MQNTZWLQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• THE USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS
  申请人：Contera Pharma APS

  公开号：EP2729176A1

  公开（公告）日：2014-05-14
• USE OF BUSPIRONE METABOLITES
  申请人：Contera Pharma APS

  公开号：EP3160464A1

  公开（公告）日：2017-05-03
• USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS
  申请人：Hansen John Bondo

  公开号：US20140243350A1

  公开（公告）日：2014-08-28

  The present invention relates to the combined use of compounds which are activators of the KCNQ family potassium ion channels and compounds which are serotonin 5-HT1 receptor agonists. The combined use of KCNQ channel activators and 5-HT1 receptor agonists is useful in the treatment of for example movement disorders. The present invention further relates to pharmaceutical compositions, methods of treatments and kits of parts.
• [EN] THE USE OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS<br/>[FR] UTILISATION D'AGONISTES DE RÉCEPTEUR DE SÉROTONINE POUR LE TRAITEMENT DE TROUBLES DES MOUVEMENTS
  申请人：CONCIT PHARMA APS

  公开号：WO2013004249A1

  公开（公告）日：2013-01-10

  The present invention relates to the combined use of compounds which are activators of the KCNQ family potassium ion channels and compounds which are serotonin 5- HT1 receptor agonists. The combined use of KCNQ channel activators and 5-HT1 receptor agonists is useful in the treatment of for example movement disorders. The present invention further relates to pharmaceutical compositions, methods of treatments and kits of parts.
• [EN] USE OF BUSPIRONE METABOLITES<br/>[FR] UTILISATION DE MÉTABOLITES DE LA BUSPIRONE
  申请人：CONTERA PHARMA APS

  公开号：WO2015197079A1

  公开（公告）日：2015-12-30

  The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.